Trial Profile
An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Alveolar soft part sarcoma; Gastric cancer; Haemangiosarcoma; Leiomyosarcoma; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Elevar Therapeutics
- 06 Apr 2023 Status changed from active, no longer recruiting to completed.
- 19 May 2022 Planned End Date changed from 15 Nov 2020 to 30 Jul 2022.
- 22 Jun 2020 Planned End Date changed from 22 Dec 2020 to 15 Nov 2020.